



Europäisches Patentamt
European Patent Office
Office européen des brevets



(11) **EP 1 674 107 A8**

(12) **CORRECTED EUROPEAN PATENT APPLICATION**

Note: Bibliography reflects the latest situation

(15) Correction information:

Corrected version no 1 (W1 A2)
Remarks

(51) Int Cl.:

A61K 38/12 (2006.01) **A61K 38/08** (2006.01)
A61K 38/05 (2006.01) **A61K 38/05** (2006.01)

(48) Corrigendum issued on:

04.10.2006 Bulletin 2006/40

(43) Date of publication:

28.06.2006 Bulletin 2006/26

(21) Application number: **06006697.4**

(22) Date of filing: **24.09.1999**

(84) Designated Contracting States:

**AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE**

Designated Extension States:

AL LT LV MK RO SI

(30) Priority: **25.09.1998 US 101828 P**

24.03.1999 US 125750 P

(62) Document number(s) of the earlier application(s) in
accordance with Art. 76 EPC:

99949913.0 / 1 115 417

(71) Applicant: **Cubist Pharmaceuticals, Inc.**

Lexington, MA 02421 (US)

(72) Inventors:

- **Oleson, Frederick B. Jr.**
Concord, MA01742 (US)
- **Tally, Francis P.**
Lincoln, MA 01733 (US)

(74) Representative: **Vossius & Partner**

Siebertstrasse 4
81675 München (DE)

Remarks:

This application was filed on 30 - 03 - 2006 as a
divisional application to the application mentioned
under INID code 62.

(54) **Use of daptomycin**

(57) The invention provides methods for administering a therapeutically effective amount of daptomycin while minimizing skeletal muscle toxicity. The methods provide daptomycin administration at a dosing interval of 24 hours or greater. This long dosing interval minimizes skeletal muscle toxicity and allows for higher peak concentrations of daptomycin, which is related to daptomycin's efficacy. The invention also provides methods of administering lipopeptide antibiotics other than daptomy-

cin while minimizing skeletal muscle toxicity by administering a therapeutically effective amount of the lipopeptide antibiotic at a dosage interval that does not result in muscle toxicity. The invention also provides methods of administering quinupristin/dalfopristin while minimizing skeletal muscle toxicity by administering a therapeutically effective amount of quinupristin/dalfopristin at a dosage interval that does not result in muscle toxicity.

EP 1 674 107 A8